Metabolites,
Год журнала:
2021,
Номер
11(12), С. 840 - 840
Опубликована: Дек. 4, 2021
In
recent
decades,
the
worldwide
prevalence
of
obesity
has
risen
dramatically
and
is
currently
estimated
to
be
around
20%.
Obesity
linked
an
increased
risk
comorbidities
premature
mortality.
Several
studies
have
shown
that
negatively
impacts
male
fertility
through
various
mechanisms.
This
review
aims
investigate
molecular
mechanisms
which
impairs
reproduction,
including
obesity-associated
hypogonadism
its
effects
on
spermatogenesis,
chronic
inflammation,
oxidative
stress.
both
conventional
biofunctional
sperm
parameters,
it
also
induces
epigenetic
changes
can
transferred
offspring.
Moreover,
obesity-related
diseases
are
a
dysregulation
adipocyte
function
micro-environmental
inflammatory
processes.
The
dysregulated
adipokines
significantly
influence
insulin
signaling,
they
may
detrimental
effect
testicular
function.
Sirtuins
play
important
role
in
metabolic
responses
obese
patients.
Understanding
involved
obesity-induced
infertility
could
increase
our
ability
identify
novel
targets
for
prevention
treatment
related
consequences.
Journal of Translational Medicine,
Год журнала:
2019,
Номер
17(1)
Опубликована: Окт. 29, 2019
The
epidemic
of
obesity
is
growing
steadily
across
the
whole
world.
Obesity
not
only
a
merely
aesthetic
disease
but
"mother"
most
chronic
diseases
such
as
associated
with
range
type
2
diabetes,
cardiovascular
disease,
obstructive
sleep
apnea,
and
cancer.
However,
although
there
need
to
find
strategy
stop
this
times
current
nutritional
strategies
are
effective
in
weight
loss
long
term
maintenance.
Very
low-calorie
ketogenic
diets
(VLCKD)
increasingly
establishing
successful
pattern
manage
obesity;
due
rapid
that
gives
rise
positive
psychological
cycle
which
turn
increases
compliance
diet.
Another
important
key
point
VLCKD
ability
preserve
fatty
free
mass
known
play
role
paramount
importance
glucose
metabolism.
Despite
clinical
evidence
paucity
data
regarding
its
management.
Therefore,
we
will
provide
useful
guide
be
used
by
nutrition
experts
taking
care
subjects
obesity.
In
particular,
report
recommendations
on
correct
use
therapeutic
approach
for
management
side
effects.
Childhood Obesity,
Год журнала:
2021,
Номер
17(4), С. 229 - 240
Опубликована: Март 29, 2021
Weight
stigma
is
rooted
in
a
fundamental
misunderstanding
of
the
origins
obesity,
wherein
interplay
behavioral,
environmental,
genetic,
and
metabolic
factors
deemphasized.
Instead,
widespread
societal
cultural
presence
weight
fosters
misconceptions
obesity
being
solely
result
unhealthy
personal
choices.
pervasive
childhood
adolescence
can
affect
individuals
throughout
their
life.
Although
prevalence
pediatric
remains
high
world,
it
becomes
increasingly
important
to
understand
how
affects
health
outcomes
children
adolescents
with
overweight
or
including
those
rare
genetic
diseases
obesity.
We
identified
reviewed
recent
literature
(primarily
published
since
2000)
on
setting.
Articles
were
search
terms
bias,
stigma,
weight-based
teasing
bullying,
bias
care.
In
this
narrative
review,
we
discuss
as
relates
complex
etiology
well
describe
best
practices
for
avoiding
perpetuating
care
Annual Review of Medicine,
Год журнала:
2023,
Номер
74(1), С. 125 - 139
Опубликована: Янв. 27, 2023
Nearly
half
of
Americans
are
projected
to
have
obesity
by
2030,
underscoring
the
pressing
need
for
effective
treatments.
Glucagon-like
peptide
1
receptor
agonists
(GLP-1
RAs)
represent
first
agents
in
a
rapidly
evolving,
highly
promising
landscape
nascent
hormone-based
therapeutics.
With
understanding
neurobiology
expanding,
these
emerging
entero-endocrine
and
endo-pancreatic
combined
or
coformulated
with
GLP-1
RAs
herald
new
era
targeted,
mechanism-based
treatment
obesity.
This
article
reviews
previews
imminent
future
nutrient-stimulated
anti-obesity
Obesity Pillars,
Год журнала:
2022,
Номер
1, С. 100004 - 100004
Опубликована: Янв. 15, 2022
The
Obesity
Medicine
Association
(OMA)
Clinical
Practice
Statement
(CPS)
regarding
definition,
diagnosis,
bias,
standard
operating
procedures
(SOPs)
and
telehealth
is
intended
to
provide
clinicians
an
overview
of
obesity
medicine
basic
organizational
tools
towards
establishing,
directing,
managing,
maintaining
medical
practice.
This
CPS
based
upon
published
scientific
citations,
clinical
perspectives
OMA
authors,
peer
review
by
leadership.
has
defined
as:
"A
chronic,
progressive,
relapsing,
treatable
multi-factorial,
neurobehavioral
disease,
wherein
increase
in
body
fat
promotes
adipose
tissue
dysfunction
abnormal
mass
physical
forces,
resulting
adverse
metabolic,
biomechanical,
psychosocial
health
consequences."
While
index
may
be
sufficiently
diagnostic
for
populations
many
patients,
accurate
diagnosis
adiposity
individual
require
anthropometric
assessments
beyond
weight
alone
(e.g.,
waist
circumference,
percent
fat,
android/visceral
fat).
complications
can
categorized
as
"sick
disease"
(adiposopathy)
and/or
"fat
disease."
predominantly
origins
include
sleep
apnea
orthopedic
conditions.
due
adiposopathic
endocrinopathies
immunopathies
cardiovascular
cancer,
elevated
blood
sugar,
pressure,
dyslipidemia,
fatty
liver,
alterations
sex
hormones
both
males
(i.e.,
hypogonadism)
females
polycystic
ovary
syndrome).
treatment
begins
with
proactive
steps
avoid
including
patient-appropriate
language,
office
equipment,
supplies.
To
help
manage
its
complications,
this
provides
a
practical
template
practice,
creation
procedures,
incorporation
the
"ADAPT"
method
(Assessment,
Diagnosis,
Advice,
Prognosis,
Treatment).
"Obesity
Definition,
Bias,
Standard
Operating
Procedures
(SOPs),
Telehealth"
one
series
CPSs
designed
assist
care
patients
disease
obesity.
BMJ,
Год журнала:
2024,
Номер
unknown, С. e072686 - e072686
Опубликована: Март 25, 2024
Abstract
Recent
publicity
around
the
use
of
new
antiobesity
medications
(AOMs)
has
focused
attention
patients
and
healthcare
providers
on
role
pharmacotherapy
in
treatment
obesity.
Newer
drug
treatments
have
shown
greater
efficacy
safety
compared
with
older
treatments,
yet
access
to
these
is
limited
by
providers’
discomfort
prescribing,
bias,
stigma
obesity,
as
well
lack
insurance
coverage.
Now
more
than
ever,
must
be
able
discuss
risks
benefits
full
range
available
patients,
incorporate
both
guideline
based
advice
emerging
real
world
clinical
evidence
into
daily
practice.
The
tremendous
variability
response
means
that
clinicians
need
a
flexible
approach
takes
advantage
specific
features
medication
selected
provide
best
option
for
individual
patients.
Future
research
needed
how
practice
settings,
potential
combination
therapies,
cost
effectiveness
medications.
Several
are
being
evaluated
ongoing
trials,
suggesting
future
obesity
bright.
Obesity,
Год журнала:
2024,
Номер
32(9), С. 1613 - 1631
Опубликована: Июнь 10, 2024
The
improved
efficacy
and
generally
favorable
safety
profile
of
recently
approved
emerging
antiobesity
medications
(AOMs),
which
result
in
an
average
weight
reduction
≥15%,
represent
significant
advancement
the
treatment
obesity.
This
narrative
review
aims
to
provide
practical
evidence-based
recommendations
for
nutritional
assessment,
management,
monitoring
patients
treated
with
AOMs.
Prior
treatment,
clinicians
can
identify
preexisting
risk
factors
counsel
their
on
recommended
intakes
protein,
dietary
fiber,
micronutrients,
fluids.
During
AOMs,
ongoing
facilitate
early
recognition
management
gastrointestinal
symptoms
or
inadequate
nutrient
fluid
intake.
Attention
should
also
be
paid
other
that
impact
response
quality
life,
such
as
physical
activity
social
emotional
health.
In
context
play
active
role
supporting
obesity
improve
health
well-being
promote
optimal
medical
outcomes.
Sleep Medicine Reviews,
Год журнала:
2024,
Номер
78, С. 101996 - 101996
Опубликована: Авг. 30, 2024
Despite
the
commonly-accepted
paradigm
that
patients
with
obstructive
sleep
apnea
(OSA)
also
invariably
have
obesity,
OSA
prevalence
extends
beyond
obesity.
This
necessitates
a
reevaluation
of
screening
strategies,
biomarkers
increased
risk,
and
heightened
awareness
among
healthcare
providers
about
array
treatments
for
diverse
adult
populations.
While
obesity
contributes
importantly
to
pathogenesis,
there
is
substantial
evidence
non-anatomical
factors
play
crucial
role,
especially
in
who
do
not
In
recent
years,
notwithstanding
recognition
contributors
research
has
frequently
focused
on
weight
reduction
address
OSA.
Insights
from
past
experiences
bariatric
surgery
serve
as
lens
anticipate
potential
outcomes
emerging
anti-obesity
pharmacotherapies.
Pharmacological
alternatives,
particularly
incretin
agonists,
exhibit
promise
improvement,
but
encounter
obstacles
such
side
effects
high
costs.
With
this
comprehensive
narrative
review,
we
delve
into
complex
epidemiological
pathophysiological
connections
between
Additionally,
emphasize
importance
multifaceted
approach
treatment,
recognizing
while
management
crucial,
need
strategies
go
traditional
weight-centric
perspectives.
